GeneQuine (Teilexit) Exit

GeneQuine Biotherapeutics is a biotech company focused on the development of gene therapy-based drugs for treatment of musculoskeletal disorders. In the lead program GeneQuine develops drug candidates with potentially disease-modifying activity for treatment of osteoarthritis.
In 2017, one of GeneQuine's lead candidates was acquired by the US pharma company Flexion Therapeutics Inc.


Dr. Stanislav Plutizki

Dr. Kilian Guse

Press releases

HTGF Financing Series A GeneQuine

Series A Investment GeneQuine
GeneQuine Biotherapeutics Secures more than €9 Million in Series A Financing and Non-Dilutive Funding to Advance Gene Therapy Pipeline for Musculoskeletal Diseases Proceeds will facilitate development of GeneQuine’s gene therapy pipeline for musculoskeletal disorders and…

GeneQuine Biotherapeutics Closes Seed Financing with High-Tech Gründerfonds and Innovationsstarter Fonds Hamburg

The Hamburg, Germany-based biotech startup GeneQuine Biotherapeutics today announced the completion of a seven-figure seed financing round. Investors are the German seed funds High-Tech Gründerfonds, Bonn and Innovationsstarter Fonds Hamburg. Funding will be used to perform proof-of-concept studies with the lead…

Info & Contact


Harburger Schlossstraße 6-12
21079 Hamburg

In portfolio

12. Oct 2012